FDA: Moderna mRNA Vaccine Against Seasonal Influenza 27% More Effective episode artwork

EPISODE · Jun 19, 2026 · 1 MIN

FDA: Moderna mRNA Vaccine Against Seasonal Influenza 27% More Effective

from GoYou Flash Briefing (EN)

Il comitato consultivo della FDA ha votato all'unanimità a favore dell'approvazione del vaccino stagionale contro l'influenza mRNA-1010 di Moderna, noto come mFlusiva. I dati di Fase 3 mostrano un'efficacia superiore del 27% rispetto ai vaccini tradizionali e una risposta immunitaria più forte negli over 65. La tecnologia mRNA promette anche una risposta rapida a nuove varianti.

Episode metadata supplied by the publisher feed · Published Jun 19, 2026

Embed this episode

NOW PLAYING

FDA: Moderna mRNA Vaccine Against Seasonal Influenza 27% More Effective

0:00 1:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of GoYou Flash Briefing (EN)?

This episode is 1 minute long.

When was this GoYou Flash Briefing (EN) episode published?

This episode was published on June 19, 2026.

Can I download this GoYou Flash Briefing (EN) episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!